Exploring a new immune checkpoint pathway in bladder cancer
A New Immune Checkpoint Pathway in Human Bladder Cancer
This study is looking at a new way that bladder cancer can hide from the immune system, and it aims to find better treatments that help more patients by targeting this hidden pathway.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project ID | NIH-11211170 on NIH RePORTER |
What this research studies
This research investigates a newly identified immune checkpoint pathway in bladder cancer, which could lead to more effective treatments. The study focuses on understanding how the KIR3DL3-HHLA2 pathway functions and its role in suppressing the immune response against bladder cancer cells. By examining the cellular and molecular mechanisms involved, the researchers aim to develop novel immunotherapies that target this pathway. This work is crucial as current treatments only benefit a small percentage of patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with bladder cancer, particularly those who have not responded to existing PD-1/PD-L1 inhibitors.
Not a fit: Patients with non-cancerous bladder conditions or those whose bladder cancer is not amenable to immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new immunotherapy options for bladder cancer patients, potentially improving survival rates and treatment outcomes.
How similar studies have performed: While the KIR3DL3-HHLA2 pathway is a novel focus, similar immune checkpoint inhibitors have shown promise in other cancers, indicating potential for success in this area.
Where this research is happening
Bronx, United States
- Albert Einstein College of Medicine — Bronx, United States (Active)
Researchers
- Principal investigator: Zang, Xingxing — Albert Einstein College of Medicine
- Study coordinator: Zang, Xingxing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.